Strategic partnerships My Personal Therapeutics collaborates with Mount Sinai and has expanded its licensed technology rights, indicating a readiness for channel partnerships and co-development deals that can be leveraged to accelerate market reach and credibility.

Clinical adoption The PDP approach provides a comprehensive, personalized drug screening workflow that integrates tumor profiling, patient avatars, and tumor board recommendations, presenting a compelling value proposition for hospitals and cancer centers seeking precision medicine solutions.

Funding signals Past government grant support demonstrates validated interest in their technology from funding bodies, suggesting opportunities for additional grants, pilots, or co-funding arrangements with health systems or research institutions.

Market focus With a London base and a North American collaboration footprint, there is potential to expand into additional international markets and larger hospital networks, appealing to institutions seeking advanced translational oncology services.

Technology edge The combination of whole exome sequencing, high-throughput fruit fly screening, and AI-driven drug matching positions MPT as a differentiated provider; sales strategies can emphasize scalability to larger tumor boards and integrated care pathways.